Ultragenyx's new manufacturing site in Bedford, MA (Credit: Ultragenyx)

Ul­tragenyx opens new gene ther­a­py man­u­fac­tur­ing site in Mass­a­chu­setts

The rare dis­ease play­er Ul­tragenyx will pro­duce its gene ther­a­pies in-house as it opens the doors to a new man­u­fac­tur­ing fa­cil­i­ty, which will lessen its re­liance on ex­ter­nal con­tract man­u­fac­tur­ers.

Ul­tragenyx an­nounced Wednes­day that it of­fi­cial­ly opened its 110,000-square-foot man­u­fac­tur­ing fa­cil­i­ty on a 10.7-acre site in the Boston sub­urb of Bed­ford, MA. The site en­ables Ul­tragenyx to pro­duce gene ther­a­pies in 2,000-liter batch­es ver­sus the in­dus­try stan­dard of 50 liters per batch. Con­struc­tion on the site be­gan in 2020. The cost of the fa­cil­i­ty was not dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.